Travere Therapeutics, Inc.
TVTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTravere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The $5.27B market capitalization puts TVTX squarely in mid-cap range for its industry. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Market Cap
$5.27B
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
11.69
EPS (TTM)
$-0.51
EPS (Fwd)
$4.85
ROE
-69.4%
ROA
-6.5%
Cash
$264.7M
Total Debt
$327.7M
Free CF
-$51.2M
52W Change
252.0%
Annual Financials
Cash vs Debt
The company holds $264.7M in cash, though total debt stands at $327.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$51.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -69.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $109.5M (2022) to $490.7M (2025), reflecting a 348% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Travere Therapeutics, Inc. and its sector.